Evidence map›Paper›PMID 16301994›Full record

ArticleOncogene2006

Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes.

P C White, A M Shore, M Clement, J McLaren, I Soeiro, E W-F Lam, P Brennan

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. CREB and leukemogenesis.Critical reviews in oncogenesis · 2011
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

P C WhiteMedical Biochemistry and Immunology, Henry Wellcome Building, Cardiff University, Heath Park, Cardiff, UK.
A M Shore
M Clement
J McLaren
I Soeiro
E W-F Lam
P Brennan
Cardiff University · GBCancer Research UK · GBHammersmith Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphocyte proliferation is key to the regulation of the immune system. Cyclin D2 is the first cell cycle protein induced following stimulation through the T-cell receptor, the B-cell receptor or cytokines. The promoter of this cyclin integrates a diverse range of signals. Through investigating the regulation of this promoter by interleukin-2 and phosphatidylinositol 3-kinase, we have identified a role for the transcription factor CREB, cAMP response element-binding protein. Mutation of the CREB-binding site reduced cyclin D2 promoter activity 5-10-fold. CREB-1 is phosphorylated at serine 133, a critical site for activity, in both T cells and Epstein-Barr virus immortalized B cells. The introduction of an S133A mutant of CREB-1 reduces IL-2 induction of cyclin D2 promoter activity, demonstrating a role for this phosphorylation site in promoter activity. Two inhibitors of protein kinase A reduce lymphocyte proliferation and CREB-1 phosphorylation. This study demonstrates that the cyclin D2 promoter is capable of being regulated by PI3K and CREB and identifies CREB-1 and protein kinase A as potential targets for altering lymphocyte proliferation.

Indexed as

Promoter Regions, GeneticBlotting, WesternB-LymphocytesCarbazolesCell ProliferationCells, CulturedCell Transformation, ViralCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinCyclin D2CyclinsElectrophoretic Mobility Shift AssayEnzyme InhibitorsHumansIndolesInterleukin-2CarbazolesCCND2 protein, humanCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinCyclin D2CyclinsEnzyme InhibitorsIndolesInterleukin-2IsoquinolinesKT 5720N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamidePhosphatidylinositol 3-KinasesProtein Kinase InhibitorsPyrrolesSulfonamides

Identifiers

PMID16301994
OpenAlexW1982627161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.